8-K: XOMA Completes LAVA Therapeutics Acquisition

XOMA Royalty Corporation announced the completion of its tender offer and acquisition of LAVA Therapeutics N.V., including a Post-Offer Reorganization.

Summary

• XOMA Royalty Corporation has completed its acquisition of LAVA Therapeutics N.V., a transaction previously disclosed.
• The acquisition was executed through a tender offer that commenced on August 15, 2025, following a share purchase agreement dated August 3, 2025, and amended on October 17, 2025.
• The offer consideration for each LAVA common share was $1.04 in cash and one non-transferable contractual contingent value right (CVR).
• The Subsequent Offering Period for the tender offer expired as scheduled on November 20, 2025.
• A Post-Offer Reorganization was effectuated and became effective on November 20, 2025.
• LAVA shareholders who did not tender their shares prior to the expiration of the Subsequent Offering Period will receive the offer consideration (cash and CVRs) through the Post-Offer Reorganization.
• XOMA issued a press release on November 21, 2025, announcing the expiration of the Subsequent Offering Period and the effectuation of the Post-Offer Reorganization.
• Financial statements for LAVA Therapeutics N.V. and unaudited pro forma condensed combined financial information for XOMA and LAVA will be filed in a future amendment to this Current Report on Form 8-K.

Sentiment

Score: 7

Explanation: The completion of a strategic acquisition is generally positive, indicating successful execution of corporate strategy. The use of CVRs can be seen as a balanced approach to valuation. No negative surprises were disclosed.

Positives

• Successful completion of a strategic acquisition, expanding XOMA's portfolio of assets and potential royalty streams.
• The inclusion of Contingent Value Rights (CVRs) in the acquisition structure may align future value for former LAVA shareholders with the performance of LAVA's underlying assets.

Future Outlook

The filing indicates that financial statements for LAVA Therapeutics N.V. and unaudited pro forma condensed combined financial information for XOMA and LAVA will be filed in a future amendment to this Current Report on Form 8-K, providing further details on the financial impact of the acquisition.

Industry Context

The acquisition of LAVA Therapeutics N.V. by XOMA Royalty Corporation reflects a trend in the biotechnology and pharmaceutical sectors where larger entities or royalty companies acquire smaller, innovative firms to expand their intellectual property portfolios and revenue streams, particularly through contingent value rights structures that tie future payments to clinical or commercial milestones.

Stakeholder Impact

• Shareholders (XOMA): The acquisition expands XOMA's asset base and potential future royalty streams, subject to the performance of LAVA's assets.
• Shareholders (LAVA): Former LAVA shareholders received $1.04 cash per share and one CVR, providing immediate liquidity and potential future payments based on LAVA's performance.
• Employees (LAVA): Implied integration into XOMA's structure, though specific details on employee impact are not provided.

Next Steps

• Filing of LAVA Therapeutics N.V.'s financial statements as of and for the years ended December 31, 2024 and 2023, and unaudited statements as of September 30, 2025 and 2024, in an amendment to this 8-K.
• Filing of unaudited pro forma condensed combined financial information of XOMA and LAVA as of and for the nine months ended September 30, 2025, and the year ended December 31, 2024, in an amendment to this 8-K.

Key Dates

Keywords

XOMA Royalty Corporation, LAVA Therapeutics, Acquisition, Tender Offer, Merger, Contingent Value Rights, CVR, Biotechnology, Pharmaceuticals, SEC Filing, 8-K